Investor List:

Top Drug Delivery Series A Investors (94)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Drug Delivery investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of James Wang, General Partner at Creative Ventures
James Wang
Creative Ventures·General Partner
Sweet spot: $750K
Range: $250K - $1M
Photo of George C. Petrocheilos, Managing Partner at Catalio Capital Management
George C. Petrocheilos
Catalio Capital Management·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Baltimore (MD), Investors in Athens (Greece), Investors in New York (NY)
Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Robotics (Series B), Investors in Robotics (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Medical Devices (Seed), Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in Robotics (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Robotics (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Robotics (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Washington, D.C. (Other Lists), Investors in Cybersecurity (Seed), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Diagnostics (Seed), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Series B), Investors in Cybersecurity (Series B), Investors in Cybersecurity (Series A), Investors in Diagnostics (Series B), Investors in Cybersecurity (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Seed), Investors in Cybersecurity (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed)
Photo of Ben York, Principal at Ultranative
Ben York
Ultranative·Principal
Sweet spot: $100K
Range: $50K - $250K
Photo of Peter Parker, Managing Partner at Mission BioCapital
Peter Parker
Mission BioCapital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A)
Photo of R. Jacob Vogelstein, Managing Partner at Catalio Capital Management
R. Jacob Vogelstein
Catalio Capital Management·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Washington (D.C.), Investors in Baltimore (MD), Investors in Bethesda
Investors in AI (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Series A), Investors in AI (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in AI (Series B), Investors in Medical Devices (Series B), Investors in Washington, D.C. (Other Lists), Investors in Drug Delivery (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Series B)
Photo of Greg Kubin, General Partner at PsyMed Ventures
Greg Kubin
PsyMed Ventures·General Partner
Sweet spot: $250K
Range: $100K - $2.0M
KK
Kelvin Keh
Covalent Ventures·Managing Partner
Sweet spot: $2.0M
Range: $500K - $4.0M
Investors in Thailand, Investors in Indonesia, Investors in Boston (MA), Investors in San Francisco (CA), Investors in Singapore, Investors in Sydney (Australia), Investors in Melbourne (Australia), Investors in New Zealand
Investors in Food and Beverage (Series A), Investors in Impact (Series A), Investors in Medical Devices (Series A), Investors in Diverse Investors (Other Lists), Investors in Health IT (Series A), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Food and Beverage (Series A), Investors in Impact (Series A), Investors in Health IT (Series A), Investors in Impact (Series A), Investors in Food and Beverage (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Boston / New England (Other Lists), Investors in Drug Delivery (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Drug Delivery (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Series A), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Series A), Investors in Wellness & Fitness (Series A), Investors in Digital Health (Series A)
Photo of James C. Murray, Partner at ExSight Ventures
James C. Murray
Sweet spot: $1M
Range: $200K - $4.0M
Investors in Europe, Investors in Canada, Investors in United States
Investors in Medical Devices (Seed), Investors in Hardware (Seed), Investors in Robotics (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Hardware (Series B), Investors in Hardware (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Robotics (Series A), Investors in Robotics (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Investors who were founders (Other Lists), Investors in Health & Hospital Services (Series B), Investors in Investors who invested in female founders (Other Lists), Investors in BioTech (Seed), Investors in Investors who invested in diverse founders (Other Lists), Investors in Hardware (Seed), Investors in New York City (Other Lists), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Hardware (Series A), Investors in Medical Devices (Series A), Investors in Robotics (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Hardware (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Health & Hospital Services (Series B), Investors in Pharmaceuticals (Series B), Investors in Canada (Other Lists), Investors in Drug Delivery (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Digital Health (Series B), Investors in Hardware (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Robotics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Hardware (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Robotics (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Get new data & insights delivered to your inbox
Firms investing in this space